A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Sapacitabine (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms SEAMLESS
- Sponsors Cyclacel Pharmaceuticals
- 01 Nov 2017 According to a Cyclacel Pharmaceuticals media release, data from the study have been selected for an oral presentation at the 59th American Society of Hematology Annual Meeting.
- 09 Aug 2017 According to a Cyclacel Pharmaceuticals media release, an abstract from the study has been submitted to the American Society of Hematology (ASH), and if accepted, will be the subject of an oral or poster presentation at the 59th ASH Annual Meeting to be held December 9 - 12, 2017.
- 28 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Cyclacel Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History